Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1346) 1346
Publication (227) 227
Book Review (13) 13
Book Chapter (3) 3
Magazine Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1127) 1127
hiv infections - drug therapy (885) 885
lopinavir (828) 828
index medicus (746) 746
male (725) 725
female (704) 704
adult (627) 627
infectious diseases (621) 621
ritonavir - administration & dosage (546) 546
ritonavir (463) 463
hiv (445) 445
middle aged (403) 403
pharmacology & pharmacy (394) 394
anti-hiv agents - administration & dosage (391) 391
hiv protease inhibitors - administration & dosage (389) 389
ritonavir - therapeutic use (362) 362
pyrimidinones - administration & dosage (357) 357
drug therapy, combination (342) 342
immunology (331) 331
lopinavir/ritonavir (330) 330
antiretroviral therapy (316) 316
protease inhibitors (313) 313
anti-hiv agents - therapeutic use (290) 290
hiv protease inhibitors - therapeutic use (284) 284
hiv infections - virology (280) 280
viral load (280) 280
treatment outcome (268) 268
pharmacokinetics (267) 267
drug therapy (242) 242
pyrimidinones - therapeutic use (239) 239
ritonavir - adverse effects (229) 229
dosage and administration (221) 221
virology (221) 221
drug administration schedule (216) 216
antiviral agents (215) 215
hiv infection (210) 210
hiv-1 - drug effects (207) 207
ritonavir - pharmacokinetics (206) 206
drug combinations (204) 204
lopinavir - administration & dosage (203) 203
hiv protease inhibitors - adverse effects (202) 202
microbiology (202) 202
human immunodeficiency virus--hiv (184) 184
therapy (182) 182
cd4 lymphocyte count (175) 175
tenofovir (172) 172
drug interactions (168) 168
hiv protease inhibitors - pharmacokinetics (166) 166
aids/hiv (165) 165
anti-hiv agents - adverse effects (165) 165
research (165) 165
anti-hiv agents - pharmacokinetics (158) 158
pyrimidinones - adverse effects (153) 153
antiretroviral drugs (151) 151
young adult (150) 150
adolescent (149) 149
atazanavir sulfate (149) 149
aids (146) 146
hiv-1 (146) 146
safety (145) 145
antiretroviral therapy, highly active (143) 143
efficacy (142) 142
highly active antiretroviral therapy (139) 139
health aspects (135) 135
pyrimidinones - pharmacokinetics (130) 130
atazanavir (129) 129
efavirenz (122) 122
lopinavir - therapeutic use (120) 120
protease inhibitor (116) 116
hiv-1-infected patients (115) 115
article (114) 114
virus diseases (114) 114
darunavir (112) 112
pyridines - administration & dosage (112) 112
adenine - analogs & derivatives (108) 108
analysis (105) 105
oligopeptides - administration & dosage (105) 105
combination (103) 103
human immunodeficiency virus (103) 103
prospective studies (103) 103
aged (102) 102
hiv infections - blood (101) 101
hiv-infected patients (100) 100
rna, viral - blood (99) 99
animals (97) 97
child (96) 96
ritonavir - pharmacology (95) 95
care and treatment (94) 94
active antiretroviral therapy (93) 93
lamivudine (91) 91
reverse transcriptase inhibitors - administration & dosage (91) 91
risk factors (91) 91
drugs (89) 89
emtricitabine (88) 88
hiv infections - complications (88) 88
hiv-1 - genetics (87) 87
lopinavir - pharmacokinetics (87) 87
antiretroviral therapy, highly active - methods (86) 86
infant (86) 86
lopinavir-ritonavir (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1286) 1286
Spanish (31) 31
German (21) 21
Japanese (5) 5
French (4) 4
Russian (4) 4
Chinese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Drug interaction profile for GSK2248761, a next generation non‐nucleoside reverse transcriptase inhibitor
by Piscitelli, Steve and Kim, Joseph and Gould, Elizabeth and Lou, Yu and White, Scott and de Serres, Mark and Johnson, Mark and Zhou, Xiao‐Jian and Pietropaolo, Keith and Mayers, Douglas
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1—Infected Patients: Week 48 Results
by Joel E. Gallant and Ellen Koenig and Jaime Andrade-Villanueva and Ploenchan Chetchotisakd and Edwin DeJesus and Francisco Antunes and Keikawus Arastéh and Graeme Moyle and Giuliano Rizzardini and Jan Fehr and Yapei Liu and Lijie Zhong and Christian Callebaut and Javier Szwarcberg and Martin S. Rhee and Andrew K. Cheng
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text 48-Week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-Infected patients: A systematic review and network meta-analysis
by Patel, Dipen A and Snedecor, Sonya J and Tang, Wing Yu and Sudharshan, Lavanya and Lim, Jessica W and Cuffe, Robert and Pulgar, Sonia and Gilchrist, Kim A and Camejo, Rodrigo Refoios and Stephens, Jennifer and Nichols, Garrett
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, p. e105653
Background: A network meta-analysis can provide estimates of relative efficacy for treatments not directly studied in head-to- head randomized controlled... 
REVERSE-TRANSCRIPTASE INHIBITOR | ANTIRETROVIRAL-NAIVE | TENOFOVIR DISOPROXIL FUMARATE | MULTIDISCIPLINARY SCIENCES | DAILY DARUNAVIR/RITONAVIR | CO-FORMULATED ELVITEGRAVIR | HIV TYPE-1 INFECTION | DOUBLE-BLIND | ONCE-DAILY ATAZANAVIR/RITONAVIR | INITIAL TREATMENT | TWICE-DAILY LOPINAVIR/RITONAVIR | HIV-1 | Lamivudine - administration & dosage | Rilpivirine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | HIV Infections - immunology | Time Factors | Lipids - blood | Antiretroviral Therapy, Highly Active - methods | Raltegravir Potassium | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Treatment Outcome | CD4 Lymphocyte Count | Adenine - administration & dosage | Randomized Controlled Trials as Topic | Organophosphonates - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Lopinavir - administration & dosage | HIV Infections - drug therapy | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | RNA | Low density lipoproteins | Analysis | DNA polymerases | Triglycerides | HIV (Viruses) | Drug therapy | HIV infection | Backbone | Lipoproteins (low density) | RNA-directed DNA polymerase | Identification methods | Ritonavir | Clinical trials | Efavirenz | Impact analysis | Literature reviews | Randomization | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Mathematical models | Safety | All terrain vehicles | Medical research | Antiretroviral drugs | Sensitivity analysis | Effectiveness | Lopinavir | Lamivudine | Ribonucleic acid--RNA | Patients | Cholesterol | CD4 antigen | Studies | Inhibitors | Abacavir | Nucleosides | Bayesian analysis | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy. The ACTG (AIDS Clinical Trials Group) Study 5152s
by Torriani, Francesca J and Komarow, Lauren and Parker, Robert A and Cotter, Bruno R and Currier, Judith S and Dubé, Michael P and Fichtenbaum, Carl J and Gerschenson, Mariana and Mitchell, Carol K.C and Murphy, Robert L and Squires, Kathleen and Stein, James H and ACTG 5152s Study Team
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2008, Volume 52, Issue 7, pp. 569 - 576
Objectives: This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus... 
endothelial function | human immunodeficiency virus | cardiovascular disease risk | antiretroviral therapy | CELLS | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | MYOCARDIAL-INFARCTION | GUIDELINES | TASK-FORCE | DISEASE | DYSFUNCTION | HIV-1 INFECTION | CARDIOVASCULAR RISK | RITONAVIR | HIV-1 | Lamivudine - administration & dosage | Prospective Studies | Humans | Endothelium, Vascular - drug effects | Male | Stavudine - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Time Factors | Adult | Brachial Artery - physiopathology | Female | Brachial Artery - drug effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | Lopinavir | CD4 Lymphocyte Count | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Endothelium, Vascular - pathology | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | HIV Infections - physiopathology | Studies | Ultrasonic imaging | Human immunodeficiency virus--HIV | Deflation | Aging | Clinical trials | Infections | Diabetes | Drug therapy | Risk factors | Cholesterol | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Antiretroviral drug exposure in the female genital tract: Implications for oral pre- and post-exposure prophylaxis
by Dumond, Julie B and Yeh, Rosa F and Patterson, Kristine B and Corbett, Amanda H and Jung, Byung Hwa and Rezk, Naser L and Bridges, Arlene S and Stewart, Paul W and Cohen, Myron S and Kashuba, Angela D.M
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
by Eron, Joseph and Yeni, Patrick and Gathe, Joseph and Estrada, Vicente and DeJesus, Edwin and Staszewski, Schlomo and Lackey, Philip and Katlama, Christine and Young, Benjamin and Yau, Linda and Sutherland-Phillips, Denise and Wannamaker, Paul and Vavro, Cindy and Patel, Lisa and Yeo, Jane and Shaefer, Mark and KLEAN study team
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 476 - 482
Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety... 
MEDICINE, GENERAL & INTERNAL | THERAPY | NAIVE PATIENTS | RECOMMENDATIONS | EFAVIRENZ | TENOFOVIR DF | RESISTANCE | AIDS | SOCIETY-USA PANEL | LOPINAVIR/RITONAVIR | NELFINAVIR | Dideoxynucleosides - administration & dosage | Organophosphates - administration & dosage | Lamivudine - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Humans | Lopinavir | Pyrimidinones - therapeutic use | Organophosphates - therapeutic use | Carbamates - administration & dosage | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | Reverse Transcriptase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | HIV Infections - drug therapy | Dideoxynucleosides - therapeutic use | Pyrimidinones - administration & dosage | Reverse Transcriptase Inhibitors - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Sulfonamides - administration & dosage | Dosage and administration | Protease inhibitors | Comparative analysis | Drug therapy | HIV infection | Antiviral agents | Research | Drug therapy, Combination | Health aspects | Anti-HIV agents | Antiretroviral drugs | Human immunodeficiency virus--HIV | Samples | Clinical trials | Comparative studies | Clinical medicine | Disease control
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study
by Boyd, Mark and SECOND-LINE Study Grp and SECOND-LINE Study Group
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2091 - 2099
Summary Background Uncertainty exists about the best treatment for people with HIV-1 who have virological failure with first-line combination antiretroviral... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | ZIDOVUDINE | LOPINAVIR/RITONAVIR MONOTHERAPY | CLINICAL-TRIALS | EFAVIRENZ | ANTIRETROVIRAL THERAPY | NAIVE | Nucleosides - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Humans | Male | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | Nucleotides - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Lopinavir - administration & dosage | Adult | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Raltegravir Potassium | Complications and side effects | Reverse transcriptase inhibitors | Dosage and administration | Drug therapy | HIV infection | Low income groups | Studies | Antiretroviral drugs | Plasma | Hepatitis | Consent | Human immunodeficiency virus--HIV | Homeostasis | Drug resistance | Viral infections | Cholesterol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009
by Abgrall, S and Ingle, S. M and May, M. T and Cornish, R and Costagliola, D and Mercie, P and Cavassini, M and Reekie, J and Samji, H and Gill, M. J and Crane, H. M and Tate, J and Sterling, T. R and Antinori, A and Reiss, P and Saag, M. S and Mugavero, M. J and Phillips, A and Manzardo, C and Wasmuth, J. C and Stephan, C and Guest, J. L and Sirvent, J. L. G and Sterne, J. A. C and Antiretroviral Therapy Cohort Coll and Antiretroviral Therapy Cohort Collaboration (ART-CC)
AIDS (London, England), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
To estimate the incidence of and risk factors for modifications to first antiretroviral therapy (ART) regimen, treatment interruption and death. A total of 21... 
HIV/AIDS | FRENCH-HOSPITAL-DATABASE | INFECTIOUS DISEASES | competing-risk method | VIROLOGICAL TREATMENT FAILURE | survival | AIDS | COMPETING RISKS | IMMUNOLOGY | DISCONTINUATION | switch | PROTEASE INHIBITOR | antiretroviral | VIROLOGY | ACTIVE ANTIRETROVIRAL THERAPY | interruption | SOCIETY-USA PANEL | INFECTED PATIENTS | COHORT | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
by Violari, Avy and Cotton, Mark F and Gibb, Diana M and Babiker, Abdel G and Steyn, Jan and Madhi, Shabir A and Jean-Philippe, Patrick and McIntyre, James A and CHER Study Team
The New England Journal of Medicine, ISSN 0028-4793, 11/2008, Volume 359, Issue 21, pp. 2233 - 2244
The timing of initiation of antiretroviral therapy in HIV-infected infants has been debated, in part because of the potential long-term toxicity of the... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | ZIDOVUDINE | HIV-1-INFECTED CHILDREN | COHORT | REGIMENS | DISEASE PROGRESSION | HIV-1 | Lamivudine - administration & dosage | Follow-Up Studies | Humans | Infant | Male | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Ritonavir - adverse effects | Treatment Failure | Female | HIV Infections - mortality | Drug Therapy, Combination | Drug Administration Schedule | Ritonavir - administration & dosage | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | Lopinavir | Pyrimidinones - adverse effects | CD4 Lymphocyte Count | Infectious Disease Transmission, Vertical | Disease Progression | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | Antiviral agents | Control | Patient outcomes | Dosage and administration | HIV infection in children | Infants | Diagnosis | Antiretroviral drugs | Hospitals | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Mortality | Infections | Drug therapy | Age | Children & youth | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
by Molina, Jean-Michel and Andrade-Villanueva, Jaime and Echevarria, Juan and Chetchotisakd, Ploenchan and Corral, Jorge and David, Neal and Moyle, Graeme and Mancini, Marco and Percival, Lisa and Yang, Rong and Wirtz, Victoria and Lataillade, Max and Absalon, Judith and McGrath, Donnie and CASTLE Study Team
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2010, Volume 53, Issue 3, pp. 323 - 332
BACKGROUND:Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48 weeks, with less gastrointestinal... 
CASTLE study | HIV-1 | Combination antiretroviral therapy | Atazanavir/ritonavir | Treatment-naive patients | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | ADULTS | IMMUNOLOGY | REGIMENS | ADHERENCE | HIV-INFECTED PATIENTS | THERAPY | DIDANOSINE | EFAVIRENZ | DRUGS | atazanavir/ritonavir | SAQUINAVIR/RITONAVIR | combination antiretroviral therapy | treatment-naive patients | Humans | Middle Aged | Male | RNA, Viral - blood | Oligopeptides - adverse effects | Viral Load | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | HIV-1 - isolation & purification | Lipids - blood | Aged, 80 and over | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Antiretroviral Therapy, Highly Active - methods | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Ritonavir - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Lopinavir | Pyrimidinones - adverse effects | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Deoxycytidine - analogs & derivatives
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1—Infected Patients: 156-Week Results From STARTMRK
by Jürgen K. Rockstroh and Jeffrey L. Lennox and Edwin DeJesus and Michael S. Saag and Adriano Lazzarin and Hong Wan and Monica L. Walker and Xia Xu and Jing Zhao and Hedy Teppler and Mark J. DiNubile and Anthony J. Rodgers and Bach-Yen Nguyen and Randi Leavitt and Peter Sklar and STARTMRK Investigators
Clinical Infectious Diseases, ISSN 1058-4838, 10/2011, Volume 53, Issue 8, pp. 807 - 816
Background. We compared 3 years of antiretroviral therapy with raltegravir or efavirenz as part of a combination regimen in the ongoing STARTMRK study of... 
HIV/AIDS | Antiretrovirals | Fasting | HIV | Body fat | Response rates | Viruses | Lipids | Fats | Virology | HIV 1 | INFECTIOUS DISEASES | RESISTANT HIV-1 INFECTION | MULTICENTER | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | THERAPY | DOUBLE-BLIND | LOPINAVIR/RITONAVIR | SUBGROUP | Humans | Male | RNA, Viral - blood | Viral Load | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Absorptiometry, Photon | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Usage | Drug utilization | HIV patients | Dosage and administration | Drug therapy, Combination | Drug therapy | Efavirenz | Raltegravir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights